youtube_live
Q4 2026 earnings • in 3 days
See detailschevron_right
COR:NYSE
Cencora Inc
$330.84
arrow_upward
+0.09%(+0.31) 1D
$326.52
arrow_downward
-1.31% (-4.32)bedtimeAfter hours
Closed: Oct 30, 3:00:09 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for COR...
Open
$336.79
High
$340.19
Low
$330.20
Mkt. cap
14.62B
Avg. vol.
1.26M
Volume
1.35M
52-wk high
$377.54
52-wk low
$244.82
Beta
0.58
Shares outstanding
190.83M
No. of employees
49K
Open
$336.79
High
$340.19
Low
$330.20
Mkt. cap
14.62B
Avg. vol.
1.26M
Volume
1.35M
52-wk high
$377.54
52-wk low
$244.82
Beta
0.58
Shares outstanding
190.83M
No. of employees
49K
News stories
From web sources and news partners
Yahoo Finance
·
15 hours ago
Cencora (COR) Stock Still Looks Undervalued After Its 173% Run
Zacks
·
2 days ago
Cencora Gears Up to Report Q4 Results: How to Play the Stock?
TradingView
·
2 days ago
Cencora Gears Up to Report Q4 Results: How to Play the Stock?
Profile
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment. The company is headquartered in Conshohocken, Pennsylvania, part of the Philadelphia metropolitan area. Wikipedia
About Cencora Inc
Analyst ratings
Based on 14 analysts giving stock ratings to COR in the past 3 months
Strong buy
Buy
11
Hold
3
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for COR in the last 3 months.
Highest
Current $330.84
$400.00 (+20.90%)
Average
$373.08 (+12.77%)
Lowest
$330.00 (-0.25%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Erin Wright Morgan Stanley | Buy | Reiterated | $377.00 | +14% | 10/30/2026 |
Eric Coldwell Robert W. Baird | Buy | Maintained | $375.00 | +13.3% | 10/22/2026 |
Allen Lutz Bank of America Securities | Hold | Reiterated | $345.00 | +4.3% | 10/21/2026 |
David Toung Argus Research | Buy | Maintained | $380.00 | +14.9% | 10/20/2026 |
Kevin Caliendo UBS | Buy | Maintained | $400.00 | +20.9% | 10/16/2026 |
Unknown Analyst Leerink Partners | Buy | Maintained | $388.00 | +17.3% | 10/07/2026 |
Ryan Halsted RBC Capital | Hold | Maintained | $330.00 | -0.3% | 10/06/2026 |
Glen Santangelo Barclays | Buy | Reiterated | $350.00 | +5.8% | 08/13/2026 |
Elizabeth Anderson CFA Evercore ISI | Buy | Maintained | $350.00 | +5.8% | 08/13/2026 |
Lisa Gill J.P. Morgan | Buy | Maintained | $390.00 | +17.9% | 08/10/2026 |
Stephen Baxter Wells Fargo | Buy | Reiterated | $395.00 | +19.4% | 08/11/2026 |
Charles Rhyee TD Cowen | Buy | Maintained | $400.00 | +20.9% | 08/09/2026 |
Daniel Grosslight Citi | Buy | Maintained | $370.00 | +11.8% | 08/06/2026 |
Ryan Daniels William Blair | Hold | Reiterated | - | - | 08/05/2026 |
Max Smock William Blair | Hold | Maintained | - | - | 05/22/2026 |
Next call in 3 days
Wed, Nov 4, 3:30 PM
Fiscal period
Q4 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $4.57
Revenue / Est. (USD)
- / 87.91B
Fiscal Q4 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 83.73B | 85.93B | 78.36B | 84.75B |
Cost of goods sold | 80.78B | 82.87B | 74.78B | 81.15B |
Cost of revenue | 80.78B | 82.87B | 74.78B | 81.15B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.75B | 1.80B | 1.98B | 2.13B |
Operating expense | 2.00B | 2.06B | 2.23B | 2.40B |
Total operating expenses | 82.78B | 84.93B | 77.01B | 83.56B |
Operating income | 944.58M | 1.00B | 1.34B | 1.20B |
Other non operating income | -49.91M | 10.10M | -173.00K | 16.88M |
EBT including unusual items | -187.04M | 708.64M | 2.09B | 996.39M |
EBT excluding unusual items | 795.23M | 941.56M | 1.20B | 1.08B |
Income tax expense | 146.03M | 142.51M | 459.04M | 219.73M |
Effective tax rate | -78.07% | 20.11% | 21.98% | 22.05% |
Other operating expenses | -4.00M | 362.00K | 595.00K | 881.00K |
Net income | -339.70M | 559.65M | 1.64B | 763.52M |
Net profit margin | -0.41% | 0.65% | 2.09% | 0.90% |
Earnings per share | 3.84 | 4.08 | 4.75 | 4.48 |
Interest and investment income | 31.52M | 20.95M | 13.88M | 13.82M |
Interest expense | -109.36M | -93.36M | -154.34M | -154.52M |
Net interest expenses | -77.83M | -72.41M | -140.46M | -140.70M |
Depreciation and amortization charges | 131.49M | 134.29M | 132.14M | 150.96M |
EBITDA | 1.21B | 1.27B | 1.60B | 1.47B |
Gain or loss from assets sale | - | -35.82M | -234.00K | -15.96M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events